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Protocol
AbstrACt
Introduction Spasticity is a common complication of 
stroke. Current therapies for poststroke spasticity (PSS) 
have been reported to be associated with high costs, lack 
of long-term benefit and unwanted adverse events (AEs). 
Electroacupuncture (EA) has been used for PSS, however, 
its efficacy and safety is yet to be confirmed by high-
quality clinical studies. This study is designed to evaluate 
the add-on effects and safety profile of EA when used in 
combination with usual care (UC).
Methods and analysis This study is a parallel group 
randomised controlled trial. A total of 136 participants will 
be included and randomly assigned to either the treatment 
group (EA plus UC) or the control group (UC alone). Prior to 
the main trial, a pilot study involving 30 participants will 
be conducted to assess the feasibility of the trial protocol. 
EA will be administered by registered acupuncturists for 
20min to 30 min, three times per week for 4 weeks. The 
primary outcome measure (Modified Ashworth Scale) and 
secondary outcome measures (Fugl-Meyer Assessment 
and Barthel Index) will be evaluated at baseline, the end 
of treatment (week 4) and the end of follow-up (week 8). 
AEs will be monitored, recorded and reported, and their 
causality will be explored.
Ethics and dissemination Ethics approval was obtained 
from the ethics committees of Guangdong Provincial 
Hospital of Chinese Medicine and RMIT University in 
December 2016. The results will be disseminated in a 
peer-reviewed journal, and PhD theses and might be 
presented at international conferences.
trial registration number ChiCTR-IOR-16010283; Pre-
results.
IntroduCtIon 
As one of the most commonly seen complica-
tions of stroke,1 2 spasticity can have a nega-
tive impact on around 20%–50% of stroke 
survivors.3 4 The direct cost for patients with 
poststroke spasticity (PSS) is reported nearly 
four times higher than those without it.5 
In clinical management of PSS, treat-
ment options include pharmacological and 
non-pharmacological interventions. Medi-
cations including oral baclofen, botulinum 
injection and chemical neurolysis may be 
considered for managing moderate or severe 
cases of PSS.1 6–11 Unwanted side effects, such 
as muscle weakness, may limit the use of 
oral antispasticity medications.12 Intrathecal 
baclofen injection is effective but usually only 
used in generalised spasticity when there 
is no response with conservative options.13 
Non-pharmacological interventions, such as 
antispastic pattern positioning and range-
of-motion exercises are recommended as 
primary treatments.1 6–11
Nevertheless, even after various treatments, 
moderate to severe disability was observed in 
more than half of patients with spasticity with 
stroke.14 Concerns have been raised about 
the unsatisfactory long-term benefit and the 
high cost of current therapies.15 16 Due to 
these limitations of current clinical manage-
ment for PSS, patients with stroke are in need 
of alternative treatment options for better 
control of spasticity with less side effects.
Acupuncture has long been practised in 
China and in recent decades it has been 
increasingly popular in the Western coun-
tries.2 Electroacupuncture (EA) involves the 
application of an electrical stimulus, where 
electric current passes between pairs of 
acupuncture needles.17 One advantage of EA 
strengths and limitations of this study
 ► Rigorous randomisation and allocation concealment 
methods will be applied with outcome assessors 
and statisticians blinded.
 ► Treatment effects on spasticity severity, motor 
function, activities of daily living, as well as adverse 
events will be observed, recorded and reported.
 ► Results will be reported complying with Consolidated 
Standards of Reporting Trials 2010 and the Revised 
Standards for Reporting Interventions in Controlled 
Trials of Acupuncture 2010.
 ► Usual care may vary across participants, potentially 
limiting the comparability of the two groups.
 ► Though widely accepted and used, the validity of the 
Modified Ashworth Scale to measure spasticity has 
been questioned.
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over manual acupuncture is that the frequency and inten-
sity can be standardised and repeated easily, ensuring 
participants in clinical studies receive the same amount of 
stimulation.7 Besides, EA was found to be more effective 
than manual acupuncture in a previous systematic review 
evaluating acupuncture for PSS.2 However, methodolog-
ical issues and inadequate reporting of included studies 
limits the certainty of these findings.2
Prior to designing this clinical trial, we had conducted 
a systematic review of EA for PSS (International prospec-
tive register of systematic reviews (PROSPERO) 2015: 
CRD42015027894).18 Twenty-two randomised controlled 
trials were included in the meta-analysis. The following 
limitations prevented us from drawing a firm conclusion 
on the effects and safety of EA for PSS: (1) methodological 
quality: none of the included trials applied appropriate 
allocation concealment, and only three studies imple-
mented blinding of outcome assessors; (2) reporting 
quality: none of the included studies addressed all key 
items recommended by the Standards for Reporting 
Intervention in Controlled Trials of Acupuncture 2010 
(STRICTA 2010)19 ; 3) absence of safety data: none of the 
included trials evaluate the safety of EA in the treatment 
for PSS.
This study aims to evaluate the effects and safety profile 
of EA for PSS and address the abovementioned limita-
tions. The main hypothesis of this trial is that, compared 
with usual care (UC, usual pharmacotherapy and/or 
rehabilitation therapies) alone, adding EA to UC will 
have an additional benefit on PSS in terms of muscle tone 
reduction, improvement of motor function of affected 
extremities and activities of daily living. The results of 
this trial will be reported in accordance with the Consol-
idated Standards of Reporting Trials (CONSORT)202010 
and STRICTA.19 It was designed following the instruc-
tions of the Standard Protocol Items: Recommenda-
tions for Interventional Trials (SPIRIT) 2013 checklist 
(online supplementary appendix 1).21 Appropriate allo-
cation concealment and blinding of outcome assessors/
statisticians will be adopted in the design of this trial, with 
evaluation of the effects and safety of EA in a 4-week treat-
ment phase and a 4-week follow-up phase.
MEthods And AnAlysIs
study design
This study will be a single-centre, outcome-assessor-blinded 
parallel randomised controlled trial consisting of a 4-week 
treatment phase followed by a 4-week follow-up phase. 
Figure 1 shows the trial procedure and table 1 details the 
trial schedule.
setting, recruitment and participants
This trial will be conducted at the Guangdong Provin-
cial Hospital of Chinese Medicine (GPHCM) in Guang-
zhou, Guangdong Province, China. Potential participants 
will be recruited through advertising posters from the 
inpatient and outpatient department of rehabilitation, 
department of acupuncture as well as the department of 
neurology of the hospital. Patients may also be referred to 
the trial by their doctors (general practitioners, neurolo-
gists, physiotherapists or acupuncturists). The recruiting 
criteria are as below:
Inclusion criteria
The inclusion criteria are: (1) people with first-ever stroke 
confirmed by CT or/and MRI; (2) 30 days to 1 year after 
stroke onset; (3) aged ≥18 years; (4) baseline Modified 
Ashworth Scale (MAS) ≥1; (5) willing to participate and 
be randomised to one of the groups.
Exclusion criteria
The exclusion criteria are: (1) people with spasticity due 
to other causes, such as multiple sclerosis, traumatic brain 
and spinal cord injuries; (2) severe and unstable clinical 
disorders; (3) unable to follow or respond to treatment 
instructions; (4) lactation, pregnancy or intend to be 
pregnant within 6 months; (5) pacemaker or implantable 
cardioverter defibrillator carriers; (6) currently enrolled 
in another clinical trial; (7) needle phobia.
Written informed consent will be sought from partici-
pants once their eligibility is confirmed. Written informa-
tion and verbal explanation of the study (including the 
purpose, procedures, time commitment, potential risks 
and benefits of the trial) will be provided before written 
consent is obtained.
All participants will receive a unique research identifi-
cation number, which will be the only identifier on data 
collection forms and in the electronic database. Elec-
tronic data will be kept confidential and stored in pass-
word-protected electronic files, and all hard-copy files will 
be stored in locked filing cabinets. Compensation for any 
harm related to the trial will be provided by GPHCM and 
will be made on a case-by-case basis.
Participants are permitted to withdraw at any time 
during the trial, with or without providing a reason. All 
withdrawn cases who have received the intervention 
will be contacted 4 weeks after withdrawal as a follow-up 
assessment, to obtain information about their condition.
randomisation and allocation concealment
Participants will be randomly allocated to an interven-
tion group (EA plus UC) or control group (UC alone) 
at a ratio of 1:1. An external statistician will provide the 
computer-generated random sequences, and implement 
allocation by a central web-based interactive randomisa-
tion service system at GPHCM. Block randomisation will 
be used to ensure equal numbers of participants are allo-
cated to the two groups. Participants will be advised not 
to reveal their group allocation to the outcome assessors 
at any time during the trial.
blinding
Due to the difficulty of blinding participants and 
acupuncturists in trials with EA, this study was designed as 
an open-label trial. Independent outcome assessors and 
 o
n
 13 M
ay 2019 by guest. Protected by copyright.
http://bmjopen.bmj.com/
BM
J O
pen: first published as 10.1136/bmjopen-2017-017912 on 27 February 2018. Downloaded from 
3Cai Y, et al. BMJ Open 2018;8:e017912. doi:10.1136/bmjopen-2017-017912
Open Access
statisticians will be blinded to group allocation throughout 
the entire trial.
Interventions
In the 4-week treatment phase, participants in both 
groups will receive UC, and those allocated to the inter-
vention group will also receive EA treatments.
UC treatment in both groups
Considering that recommendations for management 
of PSS vary across different clinical guidelines, and that 
patients with stroke may have complex comorbidities 
and complications, the UC therapies used in this trial 
will not be strictly standardised. UC for spasticity which 
is tailored for the individual may include pharmacolog-
ical and non-pharmacological interventions. Treatments 
of general internal medicine (such as blood pressure 
control, lipid-lowering medications) and rehabilitation 
therapies will be permitted. Details of UC used during 
the trial will be recorded, noting any change of UC and 
the reasons.
EA add-on treatment in the intervention group
A total of 12 EA sessions, 3 per week, will be performed 
for a period of 4 weeks. Acupuncturists who deliver the 
treatments are qualified traditional Chinese medicine 
practitioners with at least 2 years of acupuncture experi-
ence. They are required to be registered at the Chinese 
Medical Doctor Association and hold a master's degree 
in acupuncture. All EA treatment will be conducted in 
private rooms. The practitioner will explain the EA 
process and possible sensations during EA therapies to 
the participants before treatment. Immediately after each 
EA session, brief interviews will be conducted to record 
participants’ feedback about the treatment. These forms 
will be checked regularly by the investigators for consis-
tency across different acupuncture therapists.
In the EA treatment, needling may be bilateral or 
unilateral, at the acupuncturist’s discretion. Based on our 
systematic review of published EA trials for PSS,18 a list 
of acupuncture points were identified and suggested to 
be used in this trial: LI4, LI10, LI11, LI15, TE5, GB34, 
Figure 1 Flow chart.
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LR3, SP6, ST36 and ST40.22 Details of these points were 
available in online supplementary table S1. The selection 
of acupuncture points may depend on the treatment 
needed for the joints affected by spasticity, with LI4, TE5 
(wrist), LI10, LI11 (elbow), LI15 (shoulder), GB34, ST36, 
ST40 (knee), SP36 (ankle) and LR3 (toe joint) as manda-
tory points. In addition, acupuncturists will be permitted 
to select other points rather than those included in this 
list as optional points based on the individualised condi-
tion of patients. It is important to note that all acupunc-
turists will be required to select points located in the 
antagonistic muscles and avoid those located in the spas-
ticity muscles. A maximum of 10 needles, including a 
maximum of 3 pairs for EA on the affected side, will be 
inserted in each treatment session.23 Details of each EA 
treatment session including the acupuncture points will 
be documented.
Single-use stainless steel acupuncture needles of 
0.25 mm diameter (HanyiTCM, Beijing, China) will be 
used for EA treatments. Needle lengths may vary from 
25 mm to 40 mm with needle insertion depth varying 
from 15 mm to 25 mm according to the thickness of 
muscles where the EA will be conducted. ‘De qi’ sensa-
tion, an elicited response by patients, will be obtained 
before adding electric stimulation. ‘De qi’ is a composite 
of unique needling sensations, including aching, numb-
ness, distension or heaviness felt by both patients and 
acupuncturists.24 On obtaining the needling sensation, 
EA will be applied through a stimulator (G6805-I, Qing 
Dao Xinshen Industrial, Qingdao, China) with biphasic 
continuous waves at a frequency of 50–100 Hz and at the 
maximum tolerable intensity for 20–30 min.
Follow-ups
Participants in both groups will continue to receive UC 
during the 4-week follow-up phase. Participants will be 
contacted by phone at the end of week 6 for compliance 
assessment. At the end of the follow-up phase, partic-
ipants will attend the trial clinic for a final assessment, 
then participants’ involvement in the trial will cease.
outcome measures and evaluation
The primary outcome measure is the changes in MAS 
(online supplementary appendix 2) score of the major 
affected joint from baseline to the end of treatment. 
MAS measures the resistance to passive movement on a 
6-point scale (levels 0, 1, 1+, 2, 3 and 4).25 A lower score 
indicates a smaller resistance in the measured joint. MAS 
in six different joints (shoulder, elbow, wrist, hip, knee 
and ankle) in the hemiplegia side will be measured and 
recorded at baseline (week 0), end of treatment (week 4) 
and end of follow-up (week 8).
The secondary outcome measures are the Fugl-Meyer 
Assessment of motor performance (FMA (motor func-
tion)) (online supplementary appendix 3), and Barthel 
Index (BI) (online supplementary appendix 4). FMA 
(motor function) was developed from the FMA of senso-
rimotor recovery. The FMA (motor function) sums the 
scores for the upper limb (maximum score of 66) and the 
lower limb (maximum score of 34) to obtain a total score 
(maximum 100).26 A higher result in FMA suggests a 
better recovery in motor function. BI (online supplemen-
tary appendix 4) is a 10-item instrument that evaluates 
activities of daily living. Items include feeding, bathing, 
grooming, dressing, bowels, bladder, toilet use, transfers 
Table 1 Schedule of enrolment, interventions and assessments
Time point
Screening
Baseline 
assessment Treatment phase Follow-up phase
Enrolment Week 0 Weeks 1–3 Week 4 Week 6 Week 8
Eligibility screening ×
Informed consent ×
Demographic characteristics ×
History and treatment of spasticity and 
comorbidities
×
MAS × × ×
FMA × × ×
BI × × ×
EA therapy × ×
EA treatment record × ×
UC (both groups) × × × ×
AEs × × × ×
Dropouts × × × ×
Record of clinic or hospital visits × × × ×
AEs, adverse events; BI, Barthel Index; EA, electroacupuncture; FMA, Fugl-Meyer Assessment; MAS, Modified Ashworth Scale; UC, usual 
care; ×, items required.
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(bed to chair and back), mobility (on level surface) and 
stairs.27 BI establishes the degree of independence from 
physical assistance for important tasks. Scores range from 
0 to 100, with a higher score meaning less dependent to 
help.
Baseline data will be collected at the first visit by an 
independent outcome assessor, including participant’s 
family history, medical history and presenting symptoms, 
potential risk factors and aggravating factors for spasticity, 
complications and comorbidities, as well as evaluation of 
MAS, FMA and BI (table 1). At the end of the treatment 
and follow-up phases, MAS, FMA and BI will be evaluated 
by the same outcome assessor.
safety assessment
All participants will be requested to report information 
of any adverse event (AE) occurring during the trail. 
All details of AEs including the time of occurrence and 
severity will be recorded. The relationship between 
AEs and the intervention will be assessed according 
to the WHO Uppsala Monitoring Centre System for 
Standardised Case Causality Assessment.28 EA is widely 
accepted as relatively safe if applied appropriately by 
competent practitioners.29 If participants develop an 
AE during the trial, they will be advised to seek medical 
advice from their physicians and cease the EA treatment 
when the AE is considered to be EA-related and becomes 
intolerable. Severe AEs (SAEs) or severe adverse reac-
tions (SARs) are defined according to the International 
Conference on Harmonisation harmonised tripartite 
guideline30 and must be reported to the ethics committee 
of GPHCM and the research team.
discontinuing interventions
The determination to discontinue the trial for a partici-
pant will be made by the research team if: (1) a serious 
poststroke complication develops; or (2) recurrent stroke 
or any other severe condition occurs leaving the patient 
in a critical condition. Physicians will determine whether 
the participants should cease the trial participation in the 
event of an SAE or SAR.
data collection, management and monitoring
Information of the participants, instrument measures 
and other relevant data will be collected at the baseline, 
post-treatment and follow-up assessments. AEs will be 
observed and recorded during the 8-week duration of 
the trial. The case report form (CRF) including EA treat-
ment records will be paper-based. All corrections made 
to the CRFs must be personally signed and dated by the 
person responsible. All data will then be entered into a 
predesigned, password-protected electronic data set by 
two independent investigators who are blinded to group 
allocation. Double-checking of entered data will be 
performed by another researcher to ensure accuracy. The 
original CRFs and all other forms will be kept securely in 
GPHCM. Only members of the trial research team will 
have access to the final trial data set.
Data and progress monitoring will be conducted by 
an independent researcher outside the research team 
every 2 weeks throughout the trial. The independent data 
management team will monitor the safety and implemen-
tation of the trial, and will have access to group allocation.
sample size calculation
A pilot study of 30 participants will be conducted to test 
the feasibility of the trial protocol prior to a full-scale 
trial. Sample size estimation for the full-scale trial is based 
on a meta-analysis of six trials reporting MAS.29 31–35 The 
assumption is that adding EA to UC is more effective than 
UC alone. Accordingly, the EA group and the UC group 
would show a decrease of 1.22 and 0.79 in MAS scores, 
respectively, with an SD of 0.72 in each group. Sample size 
was estimated using software power analysis and sample 
size V.11.0 (NCSS, Kaysville, Utah, USA), with a signifi-
cance level (α=0.05) of a two-sided two-sample t-test and 
80% power to detect a difference between the two groups. 
A total sample size of 136 will be required, allowing 
for equal allocation to the two groups and 15% loss of 
follow-ups. On completion of the pilot study, results of 
the main outcomes will be used to adjust the sample size 
estimation for the full-scale trial.
statistical analysis
The Statistical Package for the Social Sciences software 
V.20.0 for Windows (IBM SPSS Statistics, IBM Corp, 
Somers, New York, USA) and SAS V.9.2 (SAS Institute, 
Cary, North Carolina, USA) will be used for data analysis. 
For all analyses, the statistical significance levels were set 
at 5% (ɑ=0.05).
Demographic and other baseline characteristics will 
be summarised for each group. Categorical variables 
will be presented using frequencies and percentages, 
and continuous variables using standard measures of 
central tendency and dispersion with mean and SD if 
data are normally distributed. Data not normally distrib-
uted will be presented using median and IQR will be 
used.
To compare the changes of primary and secondary 
outcomes (MAS, FMA and BI) between groups, a supe-
riority independent sample t-test with a 95% CI will be 
conducted. Further, repeated measures analysis of vari-
ance or a liner mixed model will be applied to analyse 
the changes of MAS, FMA and BI across three testing 
time points (weeks 0, 4 and 8). AEs will be expressed 
by tabulations and presented with descriptive statistics. 
Frequencies and percentages for AEs will also be analysed 
using χ2 test or Fisher’s exact test to detect between-group 
differences.
Efficacy analyses will be performed using an intent-
to-treat approach. Missing data will be replaced by 
the multiple imputation method. Ten imputed data sets 
will be created under the assumption that missing data 
are random. Result of the trial will then be the pooled 
intervention effects based on the analyses of the data sets 
with multiple imputations.
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Sensitivity analyses will be performed to assess the 
unimputation and complete case analyses. In addition, to 
adjust for hypothesised residual baseline imbalances and 
to assess their impact on effect estimates, a multivariable 
analysis will be performed. Moreover, subgroup anal-
ysis of muscle tone measured by MAS will be conducted 
with regard to age (<65 years and ≥65 years), gender, 
different types of stroke, baseline MAS, affected joints 
and length of the poststroke period to specify effects of 
EA in these domains.
EthICs And dIssEMInAtIon
The trial protocol has been approved by the Ethics 
Committee of GPHCM (online supplementary appendix 
5, 6) and the Royal Melbourne Institute of Technology 
(RMIT) University Human Research Ethics Committee 
(online supplementary appendix 7) in December 2016 
in accordance with the related Chinese ethics audit 
regulations and the Australian National Health and 
Medical Research Council’s National Statement of 
Ethical Conduct in Human Research.36–38 Any modifi-
cation in protocol is not expected unless necessary. Any 
change in the selection criteria or methodology will be 
discussed with the entire research team and approved by 
the ethics committees. The results will be published in 
a peer-reviewed journal, a PhD thesis and presented at 
conferences. Data will be published in aggregate to avoid 
individual participant identification and presented in 
such a way that identifiable data are removed.
dIsCussIon
summary of the trial
Based on the results of synthesis results of a systematic 
review,18 this trial was designed to evaluate the effects 
and safety of EA plus UC for PSS with a semipragmatic 
EA intervention protocol. Evaluation of MAS, FMA and 
BI, as well as AEs, will be recorded and reported in a 
4-week treatment and 4-week follow-up period. More-
over, this study will incorporate appropriate allocation 
concealment and blinding of assessors/statisticians and 
will be reported in accordance with CONSORT 2010 and 
STRICTA 2010.19 20
EA treatment protocol
EA treatment protocol, including the electrical stimula-
tion frequency, optional acupuncture points, number, 
frequency and duration of treatment, was designed based 
on the results of a systematic review.18 It is worth noting 
that although there is no consensus on the selection of 
acupuncture points for EA in PSS, it had been reported 
that electrical stimulation might induce muscle contrac-
tion.39 Acupuncture practitioners will be required to 
avoid stimulating acupuncture points located in the 
spasm muscles, and the maximum number of acupunc-
ture points for EA on the affected side of the body will be 
limited to three pairs.23 Selection of appropriate electrical 
stimulation frequency was one of the major challenges in 
the study design. We referred to the results of our system-
atic review18 and selected a biphasic continuous waveform 
(50–100 Hz) at patients’ maximum tolerable intensity for 
the following reasons: first, there is no specific instruc-
tion or consensus for electrical stimulation frequency 
and waveform from existing publications that could 
guide EA parameters' selection for spasticity; second, it 
was reported that low electrical stimulation frequency 
is likely to induce visible muscle contraction;39 third, all 
published randomised controlled trials included in the 
meta-analysis18 used biphasic continuous waveforms. 
After discussion with acupuncturists in GPHCM, where 
the trial will be conducted, we decided to use biphasic 
continuous waveforms (50–100 Hz) in this trial.
Control method for EA trial
In order to achieve a more pragmatic control method, 
UC including pharmacotherapy and rehabilitation treat-
ment, will not be strictly standardised. Pseudoacupunc-
ture, sham acupuncture and placebo acupuncture were 
considered an inappropriate choice for control for several 
reasons. Positive treatment effects of pseudoacupunc-
ture and sham acupuncture with needle insertion have 
been observed.40–42 In this scenario, treatment effects of 
acupuncture might be underestimated when compared 
with pseudoacupuncture or sham acupuncture. Further, 
this trial will recruit patients with stroke from a hospital 
in mainland China, where EA is well accepted and 
widely used. Patients are generally familiar with EA, 
making participant's blinding difficult.2
selection of outcome measures
Due to the complex relationship between poststroke 
pathological lesions and various complications, it is diffi-
cult to attribute changes in impairment, function and 
activity after stroke to spasticity alone.43 Spasticity can 
impact on patients with stroke in various ways.15 There-
fore, the assessment of patients with stroke with spasticity 
should not be limited to the severity of spasticity alone, 
but should include a comprehensive measurement of 
motor function and activity of daily living in general.
MAS in the upper and lower extremities demonstrated 
adequate to excellent test-retest reliability among patients 
with stroke.44 In terms of inter-rater reliability, high agree-
ment was detected with MAS when assessment was made 
by a single rater, but there was poor reliability between 
different examiners, particularly for MAS in the lower 
limb.44 With regards to validity, MAS has been criticised for 
producing a global assessment of the resistance to passive 
movement of an extremity rather than a specific assess-
ment of stretch-reflex hyperexcitability.45 46 While the 
ability of the MAS to distinguish between functional and 
mechanical properties of muscle has been questioned,47 
it is considered as the primary measure of muscle spas-
ticity with widespread clinical acceptance. In fact, MAS 
is considered the current clinical gold standard, recom-
mended by the American Physical Therapy Association, 
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in the the absence of objective clinical tools for measuring 
spasticity that are clinically feasible and easily interpreted 
by clinicians.48 49 Although there has not been an offi-
cially translated Chinese version of MAS and FMA yet, the 
outcome assessor of our trial is a professional rehabilita-
tion therapist with many years’ experience of using MAS 
and FMA in clinical practice, so we consider the use of 
these outcome measures acceptable in this trial.
FMA is one of the most widely accepted and recom-
mended quantitative assessment tools to evaluate the 
recovery of patients with stroke in both clinical and research 
settings. FMA has excellent performance in reliability and 
validity50 in terms of motor function, although criticism has 
been made of the representation of distal fine motor func-
tion and finger movement.51 BI was originally published 
in 1965 and has been widely accepted, used and studied 
with adequate to excellent validity and reliability.52–54 More 
recently, a new outcome measure, the Functional Inde-
pendence Measure (FIM), was developed to replace BI for 
accessing activities of daily living.55 Uptake of this new assess-
ment tool in trials involving Chinese people with PSS is low. 
Given that BI has been widely accepted, used, studied and 
reported in China52 and that the psychometric properties 
of the FIM instrument and BI are similar,48 56 BI has been 
selected for this trial. This will allow for comparison of our 
results with other studies.
The results of the study could provide evidence of high 
methodological and reporting quality on the effects and 
safety of EA for PSS. Specifically, muscle tone, motor 
function, activities of daily living and adverse events will 
be evaluated and analysed.
trIAl stAtus
Patient recruitment began in March 2017 and is expected 
to finish at the end of 2019.
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